(2-methoxyphenyl)(pyridin-3-yl)methanone | 55030-30-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-methoxyphenyl)(pyridin-3-yl)methanone
• 英文别名: 3-(o-Methoxybenzoyl)-pyridin；3-(2-methoxybenzoyl)pyridine；2-methoxyphenyl-3-pyridyl-ketone；2-methoxyphenyl-pyridin-3-yl-ketone；(2-methoxyphenyl)-pyridin-3-ylmethanone
• CAS: 55030-30-3
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: SDNHBUNRMRBNOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (2-methoxyphenyl)(pyridin-3-yl)methanone 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以99 %的产率得到(2-hydroxyphenyl)(pyridin-3-yl)methanone
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS
  [FR] HÉTÉROCYCLES FUSIONNÉS UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR 5-HT2A

  摘要：

  The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.

  公开号：

  WO2023141225A1
• 作为产物：
  描述：

  [2-(2-methoxyphenyl)pyridin-3-yl]methanol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以98 %的产率得到(2-methoxyphenyl)(pyridin-3-yl)methanone
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS
  [FR] HÉTÉROCYCLES FUSIONNÉS UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR 5-HT2A

  摘要：

  The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.

  公开号：

  WO2023141225A1

文献信息

• [EN] SEROTONIN 5-HT2B RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DU RÉCEPTEUR 5-HT2B DE LA SÉROTONINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010080357A1

  公开（公告）日：2010-07-15

  Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

  揭示了式I的5-HT2B受体拮抗剂。还公开了制备这些化合物的方法和使用这些化合物的方法。
• A Simple, Efficient, and Recyclable Phosphine-Free Catalytic System for Carbonylative Suzuki Coupling Reaction of Aryl and Heteroaryl Iodides
  作者：Bhalchandra Bhanage、Ziyauddin Qureshi、Krishna Deshmukh、Pawan Tambade

  DOI：10.1055/s-0030-1258349

  日期：2011.1

  The carbonylative Suzuki cross-coupling reaction of arylboronic acid with aryl and heteroaryl iodides using polymer supported palladium-N-heterocyclic carbene complex (PS-Pd-NHC) as an efficient heterogeneous, recyclable catalyst is described. The developed catalytic system is found to be effective for the carbonylative coupling reaction of aryl, heteroaryl, and bicyclic heteroaryl iodides (5-iodoindole

  描述了使用聚合物负载的钯-N-杂环卡宾配合物（PS-Pd-NHC）作为有效的多相可循环催化剂，芳基硼酸与芳基和杂芳基碘化物进行羰基化Suzuki偶联反应。发现开发的催化体系对于芳基，杂芳基和双环杂芳基碘化物（5-碘吲哚和3-碘喹啉）与各种芳基硼酸衍生物的羰基化偶联反应有效，从而提供了所需产品的良好或优异的收率。由于催化剂的易于处理和简单的后处理程序，并且对环境有益且催化剂有效地可回收，该方案是有利的。 联芳基酮-硼-多相催化-钯-铃木羰基化
• A General Synthesis of Diarylketones by Means of a Three-Component Cross-Coupling of Aryl and Heteroaryl Bromides, Carbon Monoxide, and Boronic acids
  作者：Helfried Neumann、Anne Brennführer、Matthias Beller

  DOI：10.1002/chem.200800001

  日期：2008.4.18

  Pd(OAc)2/di-1-adamantyl-n-butylphosphine (cataCXium A) is highly active in the three-component Suzuki carbonylation and represents the most general catalyst system reported up to now. A broad range of aryl/heteroaryl bromides and aryl boronic acids can be coupled to the corresponding diarylketones at low catalyst loadings.

  Pd（OAc）2 /二-1-金刚烷基-正丁基膦（cataCXium A）在三组分铃木羰基化反应中具有很高的活性，是迄今为止报道的最通用的催化剂体系。各种各样的芳基/杂芳基溴化物和芳基硼​​酸可以在低催化剂负载下与相应的二芳基酮偶联。
• Therapeutically active diarylpropylamines; their pharmaceutically acceptable salts; a method for their preparation and method for their use
  申请人：Pharmacia AB

  公开号：US06313132B1

  公开（公告）日：2001-11-06

  The invention relates to novel compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and Ar are as defined in claim 1, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The compounds have anticholinergic activity, and the invention also relates to the compounds of Formula (I), the use of the compounds of Formula (I) for preparing anticholinergic drugs, the use of the compounds of Formula (I) for treating urinary tract incontinence, and methods for preparing the compounds of Formula (I).

  该发明涉及以下式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7和Ar如权利要求1中所定义，它们与生理学上可接受的酸盐形式，当该化合物可以是光学异构体形式时，包括消旋混合物和各个对映体。这些化合物具有抗胆碱能活性，该发明还涉及式（I）的化合物，使用式（I）的化合物制备抗胆碱药物，使用式（I）的化合物治疗尿道失禁，以及制备式（I）的化合物的方法。
• Serotonin 5-HT2B Receptor Inhibitors
  申请人：Cogan Derek

  公开号：US20110269742A1

  公开（公告）日：2011-11-03

  Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

  本发明涉及公开了化学式I的血清素5-HT2B受体抑制剂。还公开了制备这些化合物的方法和使用这些化合物的方法。